These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 22397569)

  • 1. The immune response to severe bacterial infections: consequences for therapy.
    Giamarellos-Bourboulis EJ; Raftogiannis M
    Expert Rev Anti Infect Ther; 2012 Mar; 10(3):369-80. PubMed ID: 22397569
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cell death during sepsis: integration of disintegration in the inflammatory response to overwhelming infection.
    Pinheiro da Silva F; Nizet V
    Apoptosis; 2009 Apr; 14(4):509-21. PubMed ID: 19199035
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunostimulation is a rational therapeutic strategy in sepsis.
    Pugin J
    Novartis Found Symp; 2007; 280():21-7; discussion 27-36, 160-4. PubMed ID: 17380786
    [TBL] [Abstract][Full Text] [Related]  

  • 4. T cells are potent early mediators of the host response to sepsis.
    Kasten KR; Tschöp J; Adediran SG; Hildeman DA; Caldwell CC
    Shock; 2010 Oct; 34(4):327-36. PubMed ID: 20386500
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunomodulatory therapy for sepsis: an update.
    Christaki E; Anyfanti P; Opal SM
    Expert Rev Anti Infect Ther; 2011 Nov; 9(11):1013-33. PubMed ID: 22029521
    [TBL] [Abstract][Full Text] [Related]  

  • 6. What is the pathophysiology of the septic host upon admission?
    Giamarellos-Bourboulis EJ
    Int J Antimicrob Agents; 2010 Dec; 36 Suppl 2():S2-5. PubMed ID: 21129934
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The inflammatory caspases: guardians against infections and sepsis.
    Scott AM; Saleh M
    Cell Death Differ; 2007 Jan; 14(1):23-31. PubMed ID: 16977333
    [TBL] [Abstract][Full Text] [Related]  

  • 8. New perspectives on immunomodulatory therapy for bacteraemia and sepsis.
    Opal SM
    Int J Antimicrob Agents; 2010 Dec; 36 Suppl 2():S70-3. PubMed ID: 21129935
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Differences in innate defense mechanisms in endotoxemia and polymicrobial septic peritonitis.
    Echtenacher B; Freudenberg MA; Jack RS; Männel DN
    Infect Immun; 2001 Dec; 69(12):7271-6. PubMed ID: 11705897
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The immune system in critical illness.
    Marshall JC; Charbonney E; Gonzalez PD
    Clin Chest Med; 2008 Dec; 29(4):605-16, vii. PubMed ID: 18954696
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Emerging drugs for the treatment of sepsis.
    Kotsaki A; Giamarellos-Bourboulis EJ
    Expert Opin Emerg Drugs; 2012 Sep; 17(3):379-91. PubMed ID: 22780561
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sepsis after major visceral surgery is associated with sustained and interferon-gamma-resistant defects of monocyte cytokine production.
    Weighardt H; Heidecke CD; Emmanuilidis K; Maier S; Bartels H; Siewert JR; Holzmann B
    Surgery; 2000 Mar; 127(3):309-15. PubMed ID: 10715987
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Modulation of human leukocyte antigen-DR on monocytes and CD16 on granulocytes in patients with septic shock using hemoperfusion with polymyxin B-immobilized fiber.
    Ono S; Tsujimoto H; Matsumoto A; Ikuta S; Kinoshita M; Mochizuki H
    Am J Surg; 2004 Aug; 188(2):150-6. PubMed ID: 15249240
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Blood purification therapy for sepsis.
    Sakata H; Yonekawa M; Kawamura A
    Transfus Apher Sci; 2006 Dec; 35(3):245-51. PubMed ID: 17110167
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Innate immunity signaling pathways: links between immunonutrition and responses to sepsis.
    Słotwiński R; Słotwińska S; Kędziora S; Bałan BJ
    Arch Immunol Ther Exp (Warsz); 2011 Apr; 59(2):139-50. PubMed ID: 21298487
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Removal of humoral mediators and the effect on the survival of septic patients by hemoperfusion with neutral microporous resin column.
    Huang Z; Wang SR; Su W; Liu JY
    Ther Apher Dial; 2010 Dec; 14(6):596-602. PubMed ID: 21118369
    [TBL] [Abstract][Full Text] [Related]  

  • 17. An update on the pathophysiology of sepsis.
    le Roux P
    SADJ; 2004 May; 59(4):163, 165. PubMed ID: 15279093
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Macrophage migration inhibitory factor and host innate immune defenses against bacterial sepsis.
    Calandra T; Froidevaux C; Martin C; Roger T
    J Infect Dis; 2003 Jun; 187 Suppl 2():S385-90. PubMed ID: 12792855
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sepsis immunopathology: perspectives of monitoring and modulation of the immune disturbances.
    Skirecki T; Borkowska-Zielińska U; Złotorowicz M; Hoser G
    Arch Immunol Ther Exp (Warsz); 2012 Apr; 60(2):123-35. PubMed ID: 22301668
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Vascular endothelial growth factor and soluble fms-like tyrosine kinase-1 in septic shock patients treated with direct hemoperfusion with a polymyxin B-immobilized fiber column.
    Ebihara I; Hirayama K; Kaneko S; Nagai M; Ogawa Y; Fujita S; Usui J; Mase K; Yamagata K; Kobayashi M
    Ther Apher Dial; 2008 Aug; 12(4):285-91. PubMed ID: 18789115
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.